Stockreport

Celgene Provides Update on ABRAXANE® Combination Therapy in the Treatment of Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer

CELGENE  (CELG) 
Last celgene earnings: 10/31 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.celgene.com
PDF TECENTRIQ® in Combination with ABRAXANE® receives accelerated approval for people with PD-L1-Positive, Metastatic Triple-Negative Breast Cancer [Read more]